Impact Announced First-Patient-In of its PARP inhibitor IMP4297 Pivotal Study
Impact Therapeutics announced the pivotal clinical study of its PARP inhibitor IMP4297 had the first patient dosed recently. IMP4297 is a new chemical entity targeting PARP developed by Impact. The Phase 1 data readout was published as 2019 ASCO abstract, showing that IMP4297 has the potential to be a best PARP inhibitor with better safety profile and wider therapeutic window. The pivotal study is a Phase II multi-center clinical trial in China to evaluate the efficacy, safety and tolerance of IMP4297 in treating advanced ovarian cancer patients with BRCA mutation who have received at least 2 prior lines of standard treatment.
Dr. Jun Bao, President and CEO, said, “It’s exciting that we started the first registrational trial for IMP4297. As we all know, PARP has been validated to be a promising target across multiple cancer types. Based on the differentiated profile of IMP4297, our team have cautiously developed the unique clinical strategy to take the advantage of IMP4297 and meet the unmet medical needs. We look forward to bringing benefit to more patients in the future.”
Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. The lead program PARP inhibitor IMP4297 is ready for Phase 3 study in China. Impact has assembled most comprehensive global DNA damage response (DDR) pipeline of novel drug candidates generated by in-house discovery platform, and now is expanding to other novel synthetic lethality targets to broaden pipeline coverage. Impact has raised $46 million USD up to date invested by recognized venture capital firms including Lilly Asia Ventures. Currently series D fundraising is ongoing.